Development of lapachol topical formulation: anti-inflammatory study of a selected formulation.

This study aimed at developing a topical formulation of lapachol, a compound isolated from various Bignoniaceae species and at evaluating its topical anti-inflammatory activity. The influence of the pharmaceutical form and different types of emulsifiers was evaluated by in-vitro release studies. The formulations showing the highest release rate were selected and assessed trough skin permeation and retention experiments. It was observed that the gel formulation provided significantly higher permeation and retained amount (3.9-fold) of lapachol as compared to the gel-cream formulation. Antinociceptive and antiedematogenic activities of the most promising formulation were also evaluated. Lapachol gel reduced the increase in hind-paw volume induced by carrageenan injection and reduced nociception produced by acetic acid (0.8% in water, i.p.) when used topically. These results suggest that topical delivery of lapachol from gel formulations may be an effective medication for both dermal and subdermal injuries.

Desenvolvimento e validação de metodologia para quantificação de alcalóides totais como berberina em fitoterápico contendo Berberis vulgaris L. / Development and validation of a method for the quantification of total alkaloids as berberine in an herbal medicine containing Berberis vulgaris L.

A Robusterina® é um produto fitoterápico, com eficácia no tratamento de disfunções do ciclo menstrual. Em sua composição encontram-se Berberis vulgaris L., de ação sedativa e antiespasmódica; Gossypium herbaceum L., enemagoga, hemostática e ocitócica; Viburnum opulus L., antiespasmódico nas cólicas menstruais. De acordo com a Resolução RDC N° 48, de 16 de março de 2004, observa-se que o produto adequa-se na definição de Fitoterápico. A presença de alcalóides em Berberis vulgaris e a ausência de metodologias analíticas de quantificação para o produto, nos incentivaram a propor e validar um método apoiando-nos na Resolução RE N° 899, de 29 de Maio de 2003. Tal metodologia fundamenta-se na determinação espectrofotométrica de alcalóides utilizando-se Dragendorff como reagente precipitante, e o sulfato de berberina MerckÒ, como substância química de referência. A curva de calibração foi determinada com seis concentrações entre 40 e 200 mg/mL. A equação da reta é y = 0,0038x + 0,0092 com R² de 0,9996. Os parâmetros robustez, precisão, especificidade, limite de detecção e quantificação e exatidão foram avaliados estatisticamente com intervalo de confiança de 95 por cento (teste t de Student, ANOVA).

Robusterina® is a herbal medicine, with effectiveness in the treatment of menstrual cycle disfunctions. Its composition includes Berberis vulgaris L., with sedative and antispasmodic action; Gossypium herbaceum L., with emmenagogue, hemostatic and ocitocic action; Viburnum opulus L., with antispasmodic action for the treatment of menstrual colics. In accordance with Resolution RDC N° 48, of 16 of March of 2004 (ANVISA, Brazil) the product meets the definition of "Fitoterápico" (phytotherapeutic agent). The presence of alkaloids in Berberis vulgaris and the absence of analytical methodologies for quantification of the product, stimulated us to develop and validate a method in accordance with Resolution RE N° 899, of 29 of May of 2003. Such methodology is based on the determination of alkaloids using a spectrophotometric method, with Dragendorff as a precipitating reagent, and using berberine sulphate, as a standard. The calibration curve was determined with six concentrations ranging between 40 and 200 mg/mL. The equation of the calibration curve is y = 0.0038x + 0.0092 with R² of 0.9996. The parameters robustness, precision, specificity, limit of detection and quantification and accuracy have been evaluated using 95 percent confidence interval (test t of Student, ANOVA).